BioGaia AB (publ) (BIOG_B) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Biogea Q3 report for 2025. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Teresa Agnew and CFO Alexander Katsinas. Please go ahead. Hi, this is Teresa Agnew, CEO of BioGaia, and Alex and I are here to present our Q3 results. So sales were 327 million SEC, which is an increase of 7% due to higher sales in America as well as Asia Pacific. Growth overall was 14% when excluding currency effects. Year to date, our growth is 8% excluding currency effects and 4% including currency. Our sales in Asia Pacific for the quarter increased by 17%, in Americas increased by 10%, and in EMEA decreased by 4%, primarily due to sales in Eastern Europe. We saw strong growth following increased media investments in the US and other prioritized direct markets such as Canada, the UK and Australia. With our increased media, we've been attracting new consumers, new consumers to the brand and enhancing our brand awareness. For the quarter, our EBIT is 86 million sec, and our EBIT margin is 26%. And as you can see, this compares to 14% EBIT margin last year. This was lower due to the metabogen impairment loss of 51 million sec. Our year-to-date EBIT margin is now 27%. Just to remind you of our BioGaia company strategy, We have three strategic pillars. The first is grow the core in which we focus on gut health, colic, oral health, as well as immune health. Our second is expansion through direct markets. And our third is breakthrough innovation. So this is where there are market creation opportunities for using probiotics in new areas. The foundations of our company are, of...